Zwitterionic metal chelators
Zwitterionic metal chelators with PCTA derivatives and targeting vectors address solubility and interaction issues, enhancing medical imaging and chemical process efficiency by improving solubility and clearance.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- CURADEL SURGICAL INNOVATIONS INC
- Filing Date
- 2025-11-19
- Publication Date
- 2026-05-28
AI Technical Summary
Existing metal chelators lack solubility in aqueous environments, result in non-specific interactions, and are not efficiently cleared from the body, leading to high background and toxicity in medical applications, and poor yield and side reactions in chemical processes.
Development of zwitterionic metal chelators with zwitterionic groups that enhance solubility, minimize non-specific interactions, and facilitate rapid equilibration and clearance, using derivatives of 3,6,9,15-Tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA) with targeting vectors like cRGD, PSMA-617, and FAPI, allowing for efficient chelation at room temperature.
Improves signal-to-background ratio and therapeutic window in medical imaging, enhances solubility and minimizes non-specific interactions in chemical processes, and facilitates efficient clearance from the body.
Smart Images

Figure US2025056175_28052026_PF_FP_ABST